medRxiv preprint doi: https://doi.org/10.1101/2020.12.09.20245175; this version posted December 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

1 BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans

Ugur Sahin^{1,2}, Alexander Muik¹, Isabel Vogler¹, Evelyna Derhovanessian¹, Lena M. Kranz¹, 2 Mathias Vormehr¹, Jasmin Quandt¹, Nicole Bidmon¹, Alexander Ulges¹, Alina Baum⁵, Kristen 3 Pascal⁵, Daniel Maurus¹, Sebastian Brachtendorf¹, Verena Lörks¹, Julian Sikorski¹, Peter 4 Koch¹, Rolf Hilker¹, Dirk Becker¹, Ann-Kathrin Eller¹, Jan Grützner¹, Manuel Tonigold¹, 5 Carsten Boesler¹, Corinna Rosenbaum¹, Ludwig Heesen¹, Marie-Cristine Kühnle¹, Asaf Poran³, 6 Jesse Z. Dong³, Ulrich Luxemburger¹, Alexandra Kemmer-Brück¹, David Langer¹, Martin 7 8 Bexon⁸, Stefanie Bolte¹, Tania Palanche¹, Armin Schultz⁷, Sybille Baumann⁷, Azita J. Mahiny¹, 9 Gábor Boros¹, Jonas Reinholz¹, Gábor T. Szabó¹, Katalin Karikó¹, Pei-Yong Shi⁶, Camila Fontes-Garfias⁶, John L. Perez⁴, Mark Cutler⁴, David Cooper⁴, Christos A. Kyratsous⁵, Philip 10 R. Dormitzer⁴, Kathrin U. Jansen⁴, Özlem Türeci¹ 11 12 13 ¹BioNTech, An der Goldgrube 12, 55131 Mainz, Germany. 14 ² TRON gGmbH – Translational Oncology at the University Medical Center of the Johannes 15 Gutenberg, University Freiligrathstraße 12, 55131 Mainz, Germany.

- ³BioNTech US, 40 Erie Street, Suite 110, Cambridge, MA 02139, U.S.A. 16
- ⁴ Pfizer, 401 N Middletown Rd., Pearl River, NY 10960, U.S.A. 17
- 18 ⁵Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Rd, Tarrytown, NY 10591, U.S.A.
- 19 ⁶University of Texas Medical Branch, Galveston, TX 77555, U.S.A.
- 20 ⁷ CRS Clinical Research Services Mannheim GmbH, Grenadierstrasse 1, 68167 Mannheim, 21 Germany
- 22 ⁸Bexon Clinical Consulting LLC, Upper Montclair, NJ 07043, U.S.A.
- 23
- 24 Correspondence: Ugur Sahin, BioNTech, An der Goldgrube 12, 55131 Mainz, Germany, Tel: 25 +49 6131 9084 1801, Email: Ugur.Sahin@biontech.de
- 26

27 BNT162b2, a lipid nanoparticle (LNP) formulated nucleoside-modified messenger RNA 28 (mRNA) encoding the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike 29 protein (S) stabilized in the prefusion conformation, has demonstrated 95% efficacy to prevent 30 coronavirus disease 2019 (COVID-19). Recently, we reported preliminary BNT162b2 safety 31 and antibody response data from an ongoing placebo-controlled, observer-blinded phase 1/232 vaccine trial¹. We present here antibody and T cell responses from a second, non-randomized 33 open-label phase 1/2 trial in healthy adults, 19-55 years of age, after BNT162b2 prime/boost 34 vaccination at 1 to 30 µg dose levels. BNT162b2 elicited strong antibody responses, with S-35 binding IgG concentrations above those in a COVID-19 human convalescent sample (HCS) 36 panel. Day 29 (7 days post-boost) SARS-CoV-2 serum 50% neutralising geometric mean titers 37 were 0.3-fold (1 µg) to 3.3-fold (30 µg) those of the HCS panel. The BNT162b2-elicited sera 38 neutralised pseudoviruses with diverse SARS-CoV-2 S variants. Concurrently, in most 39 participants, S-specific CD8⁺ and T helper type 1 (T_H1) CD4⁺ T cells had expanded, with a high 40 fraction producing interferon- γ (IFN γ). Using peptide MHC multimers, the epitopes recognised by several BNT162b2-induced CD8⁺ T cells when presented on frequent MHC alleles were 41 42 identified. CD8⁺ T cells were shown to be of the early-differentiated effector-memory 43 phenotype, with single specificities reaching 0.01-3% of circulating CD8⁺ T cells. In summary, 44 vaccination with BNT162b2 at well tolerated doses elicits a combined adaptive humoral and 45

cellular immune response, which together may contribute to protection against COVID-19. NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

46 Main

47 Introduction

Given the high impact of the pandemic caused by the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) on human society, the rapid development of safe and effectively
prophylactic vaccines is of utmost importance.

51 Lipid nanoparticle (LNP) formulated messenger RNA (mRNA) vaccine technology delivers the 52 precise genetic information of the immunogen to antigen presenting cells and elicits potent 53 immune responses². mRNA is transiently expressed, does not integrate into the genome, and is 54 degraded by physiological pathways. mRNA vaccines are molecularly well defined, and are 55 synthesized efficiently from DNA templates by in vitro transcription, which is cell- and animalorigin material-free³⁻⁵. mRNA production and LNP formulation are fast processes of high 56 57 scalability, rendering this technology suitable for rapid vaccine development and pandemic vaccine supply⁶⁻⁸. 58

59 Within 'Project Lightspeed', the joint BioNTech-Pfizer COVID-19 RNA vaccine development 60 program, two phase 1/2 umbrella trials, one in Germany (NCT04380701) and one in the USA 61 (NCT04368728) investigate a total of four RNA-LNP vaccine candidates in. Recently, we reported preliminary clinical data from these studies on the two most advanced candidates 62 BNT162b1^{9,10} and BNT162b2¹. Each candidate is an LNP-formulated, pharmacologically 63 optimized^{11,12}, N¹-methylpseudouridine (m1 Ψ) nucleoside-modified mRNA (modRNA)¹³ 64 65 administered intramuscularly as a prime-boost 21 days apart. BNT162b1 encodes a trimerized, secreted version of the receptor-binding domain (RBD) of S, whereas BNT162b2 encodes the 66 full-length SARS-CoV-2 S stabilised in the prefusion conformation (P2 S)¹⁴. 67

BNT162b2 in a 30 µg two dose regimen has been selected for advancement into an ongoing
phase 2/3 trial, guided by the totality of data obtained in the two phase 1/2 trials and NHP

challenge studies^{1,15}. In the placebo-controlled, observer-blind USA phase 1/2 trial, 70 71 immunisation of 18-55 and 65-83 year old participants with BNT162b2 at dose levels of up to 30 µg was associated with generally mild to moderate local injection site reactions and 72 73 systemic events such as fatigue, headache, and myalgia¹. BNT162b2 elicited robust S1-binding 74 immunoglobulin G (IgG) concentrations and SARS-CoV-2 neutralising titers. Geometric mean 75 50% neutralising titers (GMTs) of sera drawn from younger and older adults seven days after 76 the second dose of 30 µg BNT162b2 were 3.8-fold and 1.6-fold, respectively, the GMT of a 77 panel of COVID-19 convalescent human sera. Complementing and expanding the published findings in the USA phase 1/2 trial, we now provide data.from the German trial (NCT04380701, 78 79 EudraCT: 2020- 001038-36). We report immunogenicity and safety of prime-boost vaccination 80 with 1, 10, 20 and 30 μ g BNT162b2 in participants 19-55 years of age, including neutralising 81 antibody GMTs up to day 85 after the first dose (approximately two months after the booster 82 dose) and detailed characterisation of T cell responses, including the first identification of 83 epitopes recognised by CD8⁺ T cells induced by a COVID-19 vaccine.

84 Study design and analysis sets

85 Participants 19-55 years of age were vaccinated with BNT162b2 in Germany (Extended Data 86 Fig. 1). Participants' mean age was 40 years; 56% were female, and all were Caucasian 87 (Extended Data Table 1). Twelve participants per dose cohort were assigned to receive a 88 priming dose of 1, 10, 20 or 30 ug on day 1 and a booster dose on day 22 (Extended Data Table 89 2). One individual each in the 1 μ g dose cohort and the 10 μ g dose cohort discontinued prior to 90 the boost. In each dose group, antibody levels and virus neutralisation titers were assessed in 91 10 to 12 participants per timepoint (up to day 85, 63 days post-boost), and peripheral blood 92 mononuclear cells (PBMCs) from 8 to 10 participants were analysed for cellular immune 93 responses at baseline and day 29 (7 days post-boost) (Extended Data Table 2).

94 Safety and tolerability

95 Briefly, no serious adverse events (SAE) and no withdrawals due to related adverse events 96 (AEs) were observed at any dose level. Local reactions, predominantly pain at the injection 97 site, were mild to moderate (grade 1 and 2) and were similar in frequency and severity after the 98 priming and booster doses (Extended Data Fig. 2a and Extended Data Table 3a). The most 99 common systemic AEs were fatigue followed by headache and only two participants reported 100 fever, which was mild (Extended Data Fig. 2b and Extended Data Table 3b). Transient chills 101 were more common after the boost, dose-dependent, and occasionally severe. Muscle pain and 102 joint pain were also more common after the boost and showed dose-dependent severity. There 103 were no grade 4 reactions. Generally, reactions had their onset within 24 hours of immunisation, 104 peaked on the day after immunisation, and mostly resolved within 2-3 days. Reactions did not 105 require treatment or could be managed with simple measures (e.g. paracetamol).

106 No clinically significant changes in routine clinical laboratory values occurred after BNT162b2 vaccination. In line with previous reports for RNA-based vaccines^{1,9,10,16}, a mild drop of blood 107 108 lymphocyte counts (without concomitant neutropenia) and an increase in C-reactive protein 109 (CRP) were observed, both transient, dose-dependent and within or close to laboratory normal 110 levels (Extended Data Fig. 3). Both effects are considered pharmacodynamic markers for the 111 mode-of-action of RNA vaccines: blood lymphocyte counts transiently decrease as the 112 lymphocytes redistribute into lymphoid tissues in response to innate immune stimulation¹⁷, and CRP is a downstream effect of innate immune modulation $^{18-21}$. 113

114 Characterization of vaccine-induced antibody response

115 S1- and RBD-binding IgG concentrations and SARS-CoV-2 neutralising titers were assessed

at baseline (day 1), 7 and 21 days after the BNT162b2 priming dose (days 8 and 22), and 7, 21,

117 28 and 63 days after the booster dose (days 29, 43 and 50; day 85 for all dose levels except

118 1 µg) (Fig. 1, Extended Data Fig. 4, Extended Data Table 2).

119 The vaccine elicited strong antibody responses. Twenty-one days after the priming dose, 120 geometric mean concentrations (GMCs) of S1-binding IgG had increased in all dose cohorts, 121 with S1-binding IgG GMCs in the range of 49-1,161 U/mL and evidence of a dose level-122 dependent response only between the 1 µg and 10 µg dose levels (Fig. 1a). Seven days after the 123 booster dose (day 29), S1-binding IgG GMCs showed a strong booster response ranging from 124 691-8,279 U/mL. Antibody levels decreased over time, but with S1-binding antibody GMCs 125 still in the range of 1,384-2,991 U/mL at day 85 (63 days after the boost), and hence well above 126 that observed in a panel of sera from SARS-CoV-2 convalescent patients (631 U/mL). Similar 127 observations were made using only the RBD domain as the target antigen (Extended Data 128 Fig. 4).

129 SARS-CoV-2 50% neutralising geometric mean titers (GMTs) increased modestly and only in 130 a proportion of participants after the priming dose of BNT162b2 (Fig. 1b). By seven days after 131 the booster dose, neutralising GMTs had increased substantially to 169, 195 or 312 in 132 participants immunised with 10 µg, 20 µg or 30 µg BNT162b2, respectively. The 1 µg dose 133 level elicited only a minimal neutralizing response (GMT of 25 at seven days after the boost). 134 On day 43 (21 days after the boost), participants vaccinated with BNT162b2 dose levels 135 between 10 and 30 µg had virus neutralizing GMTs between 108 and 166. Importantly, SARS-136 CoV-2 neutralising GMTs remained stable up to day 85 (63 days after the boost) with titers 137 ranging from 120 to 181, and thus were 1.3- to 1.9-fold the convalescent serum panel 138 neutralising GMT of 94.

S1-binding IgG GMCs after the boost showed a gradual decline, which is typical of the pattern
of proliferation followed by contraction of B cells cognately activated by either natural infection
or vaccination²⁵. In contrast, GMTs initially decreased after the boost but stabilized around day
43, which implies selection and affinity maturation of functional antibodies.

143 Neutralising antibody GMTs correlated strongly with S1-binding IgG GMCs (Fig. 1c). In 144 summary, neutralizing responses and antigen-binding IgG responses elicited by BNT162b2 in 145 this study largely mirrored those observed in the U.S.A. study, and for the first time cover 146 extended follow-up until day 85.

A panel of 18 SARS-CoV-2 RBD variants identified through publicly available information²⁴ and the dominant non-RBD S variant D614G²⁵ were evaluated as targets in pseudovirus neutralisation assays. Sera collected seven days after the booster dose of BNT162b2 showed high neutralising titers to each of the SARS-CoV-2 S variants (Fig. 1d), demonstrating the breadth of the neutralising response against circulating strains.

152 Prevalence and magnitude of vaccine-induced T cell responses

153 T cell responses of 37 BNT162b2 immunised participants from whom sufficient peripheral 154 blood mononuclear cells (PBMCs) were available were analysed pre-vaccination (day 1) and 155 seven days after the booster dose (day 29) by direct ex vivo IFNy enzyme-linked 156 immunosorbent spot (ELISpot) assay (Fig. 2, Extended Data Fig. 5, Extended Data Table 2). SARS-CoV-2 S is composed of a signal peptide (aa 1-13), the N-terminal S1 protease fragment 157 158 (aa 14-685), and the C-terminal S2 protease fragment (aa 686-1273). S1 contains the RBD (aa 159 319-541), which binds to the host receptor, and S2 mediates fusion between the viral envelope and cell membrane. To deconvolute reactivity against S, CD4⁺ or CD8⁺ T cell effectors were 160 161 stimulated overnight with overlapping peptides representing different portions of the wild-type 162 sequence of SARS-CoV-2 S, namely N-terminal pools 'S pool 1' (aa 1-643) and 'RBD' (aa 1-16 fused to aa 327-528 of S), and the C-terminal 'S pool 2' (aa 633-1273). 163

164 Seven days after the boost with BNT162b2 at any of the doses, robustly expanded SARS-CoV-

165 2 S-specific CD4⁺ T cells were detectable in all 37 participants (Fig. 2a, Extended Data Fig.

166 5a). In 34 of these participants, comparison to pre-vaccination PBMCs was possible. Thirty of

167 the 34 subjects (88.2%) had de novo (not existent at baseline) CD4⁺ T cell responses against

168 both S pool 1 and S pool 2 of SARS-CoV-2. One participant had de novo response only against 169 S pool 2. The remaining three participants had de novo responses against S pool 1 and low 170 numbers of pre-existing S pool 2-reactive CD4⁺ T cells. In two of these three participants, the 171 pre-existing responses against S pool 2 were amplified by vaccination (from 91 and 188 172 spots/ 10^6 cells pre-vaccination to 1391 and 965 spots after vaccination, respectively), whereas 173 in one of the three participants, the pre-existing responses against S pool 2 remained stable (53 174 to 140 spots/ 10^6 cells). In conclusion, these data demonstrate that in 94.1% (32/34) of 175 participants, two doses of BNT162b2 induce poly-epitopic CD4⁺ T cell responses (de novo or 176 amplified) directed against both N- and C-terminal portions of S and thus against epitopes 177 outside the RBD (Extended Data Fig. 5b).

178 Although for dose levels $\geq 10 \ \mu g$ the magnitude of CD4⁺ T cell responses did not appear to be 179 dose-dependent, it varied between individuals. In the strongest responders, the S-specific CD4⁺ 180 T cell responses were more than 10-fold of the individual memory responses to common viruses 181 and recall antigens (those from cytomegalovirus, Epstein Barr virus, influenza virus and tetanus 182 toxoid) (Fig. 2b, c).

183 Vaccine-induced S-specific CD8⁺ T cell responses were detected in 34 of 37 vaccinated 184 participants (91.9%). The majority were strong responses (Fig. 2a, Extended Data Fig. 5a) 185 comparable to individual memory responses against cytomegalovirus (CMV), Epstein Barr 186 virus (EBV)and influenza virus (Fig. 2b, c). De novo S -specific CD8⁺ T cell responses were 187 induced in 33 participants, these were either directed against both (22 participants), or one of 188 the S pools (S pool 1 in ten participants, and S pool 2 in two participants), indicating a 189 preponderance of a poly-epitopic response including non-RBD S-specific T cells (Extended 190 Data Fig. 5b). In seven participants, pre-existing CD8⁺ T cell responses to S pool 2 were 191 detected that were not further augmented by vaccination. Six out of these seven participants 192 had a concurrent de novo response to pool 1 of S, which in strength did not differ significantly

193 from those observed in individuals without pre-existing responses to S pool 2 (Extended Data 194 Fig. 5c). Of note, the strongest responses (higher than third quartile) against S pool 1 among 195 the 34 participants with detectable CD8⁺ T cell responses were observed in those without pre-196 existing S pool 2-specific responses.

197 The magnitude of S-specific CD4⁺ T cell responses correlated positively with S1-binding IgG 198 (Extended Data Fig. 6a), and, in line with the concept of intramolecular help²⁶, also with the 199 strength of S-specific CD8⁺ T cell responses (Extended Data Fig. 6b). S-specific CD8⁺ T cell 200 responses also correlated positively with S1-binding IgG (Extended Data Fig. 6c), indicating a 201 convergent development of the humoral and cellular adaptive immunity.

202 Polarisation of vaccine-induced T cell responses

203 To assess functionality and polarisation of S-specific T cells, cytokines secreted in response to 204 stimulation with S pool 1, S pool 2 and RBD pool were determined by intracellular staining 205 (ICS) for IFNy, IL-2 and IL-4 specific responses in pre- and post-vaccination PBMCs of 37 206 BNT162b2-immunised participants (Extended Data Table 2). A considerable fraction of vaccine-induced, S-specific CD4⁺ T cells secreted IFNy, IL-2, or both, while T cells secreting 207 208 the T_H2 cytokine IL-4 were barely detectable (Fig. 3a-c, Extended Data Fig. 5d, e). Vaccine-209 induced S-specific CD8⁺ T cells secreted predominantly IFNy and lower levels of IL-2 in response to S pool 1 and S pool 2 stimulation. Fractions of IFN γ^+ CD8⁺ T cells specific to S 210 211 pool 1 constituted up to about 1% of total peripheral blood CD8⁺ T cells (Fig. 3d). Of note, 212 several of the analysed participants (n=3 in the 20 µg dose cohort and n=3 in the 30 µg dose 213 cohort) displayed pre-existing S pool 2 specific CD8⁺ T cell responses, which in 5 out of the 214 6 participants were not further amplified after vaccination. A strong pre-existing S pool 2 specific IFN γ^+ CD4⁺ T cell response was detectable in one participant (20 µg dose cohort) (Fig. 215 216 3c).

In both assay systems, cytokine production of CD4⁺ as well as CD8⁺ T cells in response to peptide pools comprising the full SARS-CoV-2 S exceeded the responses against the RBD peptide pool, further confirming the poly-epitopic nature of T cell responses elicited by BNT162b2. The mean fraction of BNT162b2-induced S-specific IFN γ^+ or IL-2⁺ CD4⁺ and CD8⁺ T cells within total circulating T cells was higher than that detected in eighteen control subjects who had recovered from COVID-19 (HCS) (Fig. 3c, d).

223 Epitope specificity and phenotype of CD8⁺ T cells

224 CD8⁺ T cell responses were characterised on the epitope level in three BNT162b2 vaccinated 225 participants. To this aim, pre- and post-vaccination PBMCs were stained with individualised 226 peptide/MHC multimer staining cocktails for flow cytometry analysis. Twenty-three (4 for 227 HLA-B*0702, 19 for HLA-A*2402), 14 (HLA-B*3501) and 23 (7 for HLA-B*4401, 16 for 228 HLA-A*0201) diverse peptide/MHC allele pairs were used for participants 1, 2 and 3, 229 respectively. This approach identified de novo induced CD8⁺ T cell reactivities against multiple 230 epitopes for each participant, adding up to a total of eight different epitope/MHC pairs spread 231 across the full length of S (Fig. 4a, c). The magnitude of epitope-specific T cell responses ranged 232 between 0.01-3.09% of peripheral CD8⁺ T cells, and the most profound expansion was observed 233 for HLA-A*0201 YLQPRTFLL (3.09% multimer⁺ of CD8⁺), HLA-A*2402 QYIKWPWYI 234 (1.27% multimer⁺ of CD8⁺) and HLA-B*3501 QPTESIVRF (0.17% multimer⁺ of CD8⁺). 235 Whereas the pMHC multimer approach probes a discrete subset of potential reactivities, bulk 236 IFN γ^+ CD8⁺ T cell responses against full S determined by ELISpot and ICS are considered to 237 comprehensively capture the full poly-epitopic T cell response. However, comparison of both 238 data sets indicated that a functional T cell assay may underestimate the true extent of the cellular

239 immune response (Extended Data Fig. 5f).

Phenotyping of the identified pMHC multimer⁺ S antigen-experienced CD8⁺ T cell specificities
revealed an early differentiated effector memory phenotype characterised by low expression of

CCR7 and CD45RA and high expression of the costimulatory molecules CD28 and CD27.
CD8⁺ T cells also expressed markers associated with cognate activation, such as CD38, HLADR and PD-1 (Fig. 4b).

245 **Discussion**

Effectors of the adaptive immune system have complementary roles in the defense of viral infections. While neutralising antibodies are the first line of defense, CD8⁺ cytotoxic T lymphocytes (CTLs) contribute to virus clearance from intracellular compartments that are inaccessible to neutralising antibodies. Antigen-specific CD4⁺ T cells have immune orchestrating functions, including provision of cognate help to B cells and CD8⁺ T cells, support of memory generation, as well as indirect (*e.g.* via IFN γ) or direct (against MHC class IIexpressing target cells) cytotoxic activity.

There is broad consensus reflected in the design of ongoing clinical trials that a COVID-19 vaccine should induce antibodies to SARS-CoV-2 S. However, it is not yet known if antibody responses will be sufficient for full and long-lasting protective immunity to SARS-CoV-2, and what the contribution of SARS-CoV-2-specific T cells may be.

257 Previous experience with the closely related first SARS-CoV suggests that T cells prevent severe forms of the disease²⁷ and may be associated with long-term protection^{28,29}. For the novel 258 259 SARS-CoV-2, an understanding of mechanisms of immunity from studies of infected and 260 convalescent individuals is only beginning to emerge. An increasing amount of data supports a role of T cell immune responses³⁰⁻³². COVID19 patients with critical disease states were 261 reported to lack S1-reactive CD4⁺ T cells³³. Cases of asymptomatic virus exposure have been 262 263 associated with cellular immune responses without seroconversion, indicating that SARS-CoV-264 2 specific T cells could be relevant in disease control even in the absence of neutralising antibodies²⁹. 265

We report here that vaccination with BNT162b2 induces a coordinated immune response with SARS-CoV-2 S-specific neutralising antibodies, CD4⁺ T cells, CD8⁺ T cells, and immunemodulatory cytokines such as IFNy.

269 All participants vaccinated with BNT162b2 mounted de novo S-specific CD4⁺ T cell responses 270 and almost 92% of participants mounted CD8⁺ T cell responses, as detected with an ex vivo 271 ELISpot assay. The magnitude of the T cell responses varied inter-individually and showed no 272 clear dose dependency. Even with the lowest dose of 1 µg BNT162b2, most of the vaccinated 273 participants demonstrated robust expansion of CD4⁺ and CD8⁺ T cells. T cell responses were 274 directed against RBD, S1 and S2 regions of S, indicating immune recognition of multiple 275 independent MHC I and II epitopes, which was one of the reasons to favour BNT162b2 over 276 BNT162b1.

277 Expression of IFN γ and IL-2 but only low levels of IL-4 in BNT162b2-induced CD4⁺ T cells 278 indicated a T_H1 profile and the absence of a potentially deleterious T_H2 immune response.

While all CD8⁺ T cell responses against the S1 subunit of S were de novo and not detected at baseline, pre-existing immune responses against the S2 subunit were identified in several individuals. The S1 fragment has less sequence similarity to the corresponding seasonal coronavirus sequences than the S2 fragment does, indicating that we may have detected preexisting cross-reactive CD8⁺ T cells^{34,35}.

pMHC multimer technology enabled the identification of S epitopes recognised by vaccineinduced CD8⁺ T cells as well as direct quantification of the respective epitope-specific T cells. The cumulative T cell frequencies in each participant exceeded the overall T cell response measured in ELISpot and ICS assays, indicating that those assays underestimate the true magnitude of the poly-epitopic response. Single peptide analyses are well known to yield higher T cell frequencies as compared to functional T cell assays that stimulate with peptide pools, with a multitude of immunogenic epitopes competing. A high proportion of induced CD8⁺ T

cells were early differentiated effector memory cells. This favourable phenotype has the potential to respond rapidly, but has a limited capacity to produce IFN γ , and thus is less likely to be detected in functional T cell assays. Previous studies have identified epitopes in SARS-CoV-2 S against which infected individuals raise CD8⁺ T cells^{36,37}. To our knowledge, this is the first report of epitopes recognised by COVID-19 vaccine-induced T cells. Of note, the immunodominant HLA-A*02:01 restricted peptide YLQPRTFLL identified in our study has previously been described in convalescent COVID-19 patients^{36,37}.

298 In addition to providing new insights into T cell responses, this study reproduces our previous 299 findings in the U.S.A trial¹, and confirms a benign safety profile and robust induction of 300 antibody responses, with the latter being followed up for a longer period, up to day 85 (63 days 301 post-boost). Prime/boost vaccination with 10 to 30 µg of BNT162b2 elicited GMTs that, after 302 an initial decline, remained stable up to day 85 in the range of, or higher than, GMTs in COVID-303 19 recovered individuals. BNT162b2 immune sera efficiently neutralised 19 pseudotyped 304 viruses (18 of which enter cells using an S protein with a different RBD variant, and one of 305 which uses the dominant S variant D614G), indicating the potential for broad BNT162b2elicited protection against reported mutations^{1,9,10}. 306

Limitations of our clinical study include the small sample size, the lack of representation of populations of interest (*e.g.* older adults, other ethnicities, immunocompromised individuals and pediatric populations), and limited availability of blood samples for a more in-depth T cell analysis.

Typically antigen-activated B and T cells go through proliferation, followed by rebound contraction with a gradual decline in numbers before entering a sustained memory phase^{22,23}, and the short-term follow up presented in this paper does not allow for extrapolation of longterm durability of the immune responses. Whereas it is encouraging that BNT162b2 robustly activates antigen-specific humoral and as cellular immune effector systems, it is not clear

- 316 whether this immune response pattern will protect from SARS-CoV-2 infection and prevent
- 317 COVID-19. These questions will be addressed by the ongoing clinical program, which includes
- 318 longer term follow-up of participants in the two ongoing phase 1/2 trials, a dedicated immune
- 319 biomarker trial to further dissect the composite elements of the immune response, and the
- 320 ongoing phase 2/3 study with efficacy endpoints.

321 Acknowledgements

322 We thank Mikael Dolsten, Pfizer Chief Scientific Officer, for advice during drafting of the 323 manuscript. We thank C. Anders, C. Anft, N. Beckmann, K. Bissinger, P. Cienskowski, K. 324 Clarke, C. Ecker, A. Engelmann, M. Fierek, D. Harjanto, A. Heinen, M. Hossainzadeh, S. Jägle, 325 L. Jeck, O. Kahl, D. Kallin, M. Knezovic, T. Kotur, M. Kretschmer, A. Kruithof, J. Mc Gee, B. 326 Mehlhase, C. Müller, S. Murphy, L.-M. Schmid, K. Schmoldt, R. Schulz, L. Srinivasan, M. 327 Vehreschild, T. Weisenburger and S. Wessel for technical support, project management and 328 advice. We thank P. Koch for data management and analysis. We thank O. Kistner, S. 329 Liebscher, J. Loschko and K. Swanson for expert advice. We thank Judith Absalon for 330 manuscript advice. We thank the CRS Team (Mannheim and Berlin) for study conduct: S. 331 Armani, M. Berse, M. Casjens, B. Ehrlich, F. Seitz, M. Streckebein. We thank W. Kalina, I. 332 Scully, and the Pfizer Vaccines Clinical Assays Team and the Pfizer Aviation Team for 333 technical and logistical support of serology analyses. We thank GISAID Nucleotide database 334 for sharing of SARS-CoV-2 complete genome sequences.

335 Author Contributions

336 U.S. conceived and conceptualised the work and strategy supported by Ö.T. Experiments were 337 planned or supervised by N.B., E.D., C. F.-G, C.A.K., U.L., A.M., J.Q., P.-Y.S., A.U. and I.V.. 338 A.B., N.B., D.C, M.C., C. F.-G, K.P., J.Q., A.U. and P.-Y.S. performed experiments. D.B., S. 339 Brachtendorf, E.D., P.R.D., J.G., K.U.J., A.-K.E., P.K., M.T., L.M.K., M.-C.K., V.L., A.M., 340 J.Q., J.S., N.B., A.U., I.V. and M.V. analysed data. A.P. prioritised epitopes for multimer assay. 341 J.Z.D. supervised manufacturing and delivery of peptides for multimer assay. D.M. planned 342 and supervised dashboards for analysis of clinical trial data. R.H. was responsible for data 343 normalization and adaption. C.B, L.H. and C.R. were responsible for biomarker and R&D

344 program management. G.B., K.K., A.J.M., J.R. and G.T.S. optimised mRNA characteristics.

345 A.K-B., S. Baumann, A.S., D.L., M.B., S. Bolte, and T.P. coordinated operational conduct of

- the clinical trial. J.L.P. advised on the trial. U.S., Ö.T., supported by M.B., N.B., E.D., P.R.D.,
- 347 K.U.J., L.M.K., A.M., A.U., I.V. and M.V., interpreted data and wrote the manuscript. All
- 348 authors supported the review of the manuscript.

349 **Competing interests**

The authors declare: U.S. and Ö.T. are management board members and employees at BioNTech SE (Mainz, Germany); A. K.-B., A.-K.E., A.U., C.R., D.B., P.K., D.L., D.M., E.D., J.G., J. S., M.-C.K., R.H., S. Bolte, S. Brachtendorf, T.P., U.L. and V.L. are employees at

- 353 BioNTech SE; A.J.M., A.M., G.B., G.T.S., I.V., J.R., J.Q., K.K., L.M.K., N.B., and M.V. are
- 354 employees at BioNTech RNA Pharmaceuticals GmbH; A.P. and J.Z.D are employees at
- BioNTech US; M.B. is an employee at Bexon Clinical Consulting LLC. A.B., C.A.K. and K.P.
- are employees of Regeneron Pharmaceuticals Inc; A.M., K.K., Ö.T. and U.S. are inventors on
- 357 patents and patent applications related to RNA technology and COVID-19 vaccine; A.K.-B.,
- 358 J.Z.D., A.J.M., A.M., C.R., G.B., D.B., D.L., E.D., I.V., J.G., K.K., L.M.K., A.P., M.V., N.B.,
- 359 Ö.T., R.H., S. Bolte, U.L. and U.S. have securities from BioNTech SE; D.C., M.C., P.R.D.,
- 360 K.U.J. and J.L.P. are employees at Pfizer and may have securities from Pfizer; C.A.K. is an

361 officer at Regeneron Pharmaceuticals, Inc; A.B., C.A.K. and K.P. have securities from

362 Regeneron Pharmaceuticals, Inc; C.F.-G. and P.-Y.S. received compensation from Pfizer to

perform the neutralisation assay; no other relationships or activities that could appear to haveinfluenced the submitted work.

365 Funding

- BioNTech is the Sponsor of the study and responsible for the design, data collection, data analysis, data interpretation, and writing of the report. Pfizer advised on the study and the manuscript, generated serological data, and contracted for the generation of serological data. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit the data for publication. All study data were available to all authors.
- 371 This study was not supported by any external funding at the time of submission.

372 Additional Information

- 373 Supplementary Information is available for this paper.
- 374 Correspondence and requests for materials should be addressed to Ugur Sahin.

Materials and Methods 375

376 Clinical trial design.

377 Study BNT162-01 (NCT04380701) is an ongoing, umbrella-type first-in-human, phase 1/2, 378 open-label, dose-ranging clinical trial to assesses the safety, tolerability, and immunogenicity 379 of ascending dose levels of various intramuscularly administered BNT162 mRNA vaccine 380 candidates in healthy men and non-pregnant women 18 to 55 years (amended to add 56-85 381 years) of age. The principle endpoints of the study are safety and immunogenicity. Key 382 exclusion criteria included previous clinical or microbiological diagnosis of COVID-19; receipt 383 of medications to prevent COVID-19; previous vaccination with any coronavirus vaccine; a 384 positive serological test for SARS-CoV-2 IgM and/or IgG; and a SARS-CoV-2 nucleic acid 385 amplification test (NAAT)-positive nasal swab; increased risk for severe COVID-19; and 386 immunocompromised individuals.

387 The presented data are from the BNT162b2-immunised healthy adults 19 to 55 years of age 388 exposed to dose levels 1, 10, 20 or 30 µg. The data are based on a preliminary analysis (data 389 extraction date of 23 October 2020 for safety and antibody analysis, 16 October 2020 and 24 390 November 2020 for T cell analysis [intracellular cytokine staining and ELISpot, respectively]) 391 and are focused on analysis of vaccine-induced immunogenicity descriptively summarised at 392 the various time points, and on reactogenicity. All participants with data available were 393 included in the immunogenicity analyses. This part of the study was performed at one site in 394 Germany with 12 healthy participants per dose level in a dose-escalation/de-escalation design. 395 Sentinel dosing was performed in each dose-escalation cohort. Progression in that cohort and 396 dose escalation required data review by a safety review committee. Participants received a 397 BNT162b2 priming dose on day 1, and a booster dose on day 22 ± 2 (on day 28 for one 398 participant from the 10 µg dose cohort). Serum for antibody assays was obtained on day 1 (pre-399 prime), 8±1 (post-prime), 22±2 (pre-boost), 29±3, 43±4 and 50±4 (post-boost). PBMCs for T

400 cell studies were obtained on day 1 (pre-prime) and 29±3 (post-boost) (Extended Data Fig. 1). 401 Follow-up of participants is ongoing and includes assessment of antibody and T cell responses 402 at later time points. Reactogenicity was assessed by patient diary. Two participants discontinued 403 prior to the booster dose due to study drug-unrelated withdrawal (participant in the 1 µg dose 404 cohort) and an adverse event (participant of the 10 µg dose cohort) (upper respiratory 405 syndrome), respectively. The trial was carried out in Germany in accordance with the 406 Declaration of Helsinki and Good Clinical Practice Guidelines and with approval by an 407 independent ethics committee (Ethik-Kommission of the Landesärztekammer Baden-408 Württemberg, Stuttgart, Germany) and the competent regulatory authority (Paul-Ehrlich 409 Institute, Langen, Germany). All participants provided written informed consent.

410 Manufacturing of RNA.

411 BNT162b2 incorporates a Good Manufacturing Practice (GMP)-grade mRNA drug substance 412 that encodes the trimerised SARS-CoV-2 S glycoprotein RBD antigen. The RNA is generated 413 from a DNA template by in vitro transcription in the presence of 1-methylpseudouridine-5'-414 triphosphate (m1YTP; Thermo Fisher Scientific) instead of uridine-5'-triphosphate (UTP). Capping is performed co-transcriptionally using a trinucleotide cap 1 analogue ($(m_2^{7,3^2})$ 415 ^O)Gppp(m^{2'-O})ApG; TriLink). The antigen-encoding RNA contains sequence elements that 416 increase RNA stability and translation efficiency in human dendritic cells^{11,12}. The mRNA is 417 418 formulated with lipids to obtain the RNA-LNP drug product. The vaccine was transported and 419 supplied as a buffered-liquid solution for IM injection and was stored at -80 °C.

420 **Proteins and peptides.**

Two pools of 15-mer peptides overlapping by 11 amino acids (aa) and together covering the whole sequence of wild-type SARS-CoV-2 S (S pool 1 featuring aa 1-643, S pool 2 featuring aa 633-1273) and one pool covering the SARS-CoV-2 RBD (aa 327-528) with the signal peptide of S (aa 1-16) fused to its N-terminus were used for ex vivo stimulation of PBMCs for

flow cytometry and IFNγ ELISpot. CEF (CMV, EBV, influenza virus; human leukocyte antigen
[HLA] class I epitope peptide pool) and CEFT (CMV, EBV, influenza virus, tetanus toxoid;
HLA class II epitope peptide pool) were used as controls for general T cell reactivity and to
benchmark the magnitude of memory T cell responses. All the above peptides were obtained
from JPT Peptide Technologies. The 8-12 amino acid long peptides used in the easYmer assays
were produced at BioNTech US.

431 Human convalescent serum and PBMC panel.

432 Human SARS-CoV-2 infection/COVID-19 convalescent sera (n=38) were drawn from donors 433 18-83 years of age at least 14 days after PCR-confirmed diagnosis and at a time when the 434 participants were asymptomatic. The mean age of the donors was 45 years. Neutralising GMTs 435 in subgroups of the donors were as follows: symptomatic infections, 90 (n=35); asymptomatic 436 infections, 156 (n=3); hospitalized, 618 (n=1). Sera were obtained from Sanguine Biosciences 437 (Sherman Oaks, CA), the MT Group (Van Nuys, CA) and Pfizer Occupational Health and 438 Wellness (Pearl River, NY). Human SARS-CoV-2 infection/COVID-19 convalescent PBMC 439 samples (n=18) were collected from donors 22-79 years of age 30-62 days after PCR-confirmed 440 diagnosis, when donors were asymptomatic. PBMC donors had asymptomatic or mild 441 infections (n=16, clinical score 1 and 2) or had been hospitalized (n=2, clinical score 4 and 5). 442 Blood samples were obtained from the Frankfurt University Hospital.

443 Cell culture and primary cell isolation.

Vero cells (American Type Culture Collection [ATCC] CCL-81) and Vero E6 cells (ATCC CRL-1586) were cultured in Dulbecco's modified Eagle's medium (DMEM) with GlutaMAXTM (Gibco) supplemented with 10% fetal bovine serum (FBS) (Sigma-Aldrich). Cell lines were tested for mycoplasma contamination after receipt and before expansion and cryopreservation. PBMCs were isolated by Ficoll-PaqueTM PLUS (Cytiva) density gradient centrifugation and cryopreserved prior to analysis.

450 S1- and RBD-binding IgG assay.

451 Recombinant SARS-CoV-2 S1 or RBD containing a C-terminal Avitag[™] (Acro Biosystems) 452 were bound to streptavidin-coated Luminex microspheres. Heat-inactivated participant sera 453 were diluted 1:500, 1:5,000, and 1:50,000. Following an overnight incubation at 2-8 °C while 454 shaking, plates were washed in a solution containing 0.05% Tween-20. A secondary 455 fluorescently labelled goat anti-human polyclonal antibody (Jackson Labs) was added for 456 90 minutes at room temperature while shaking, before plates were washed once more in a 457 solution containing 0.05% Tween-20. Data were captured as median fluorescent intensities 458 (MFIs) using a Bioplex200 system (Bio-Rad) and converted to U/mL antibody concentrations 459 using a reference standard curve with arbitrarily assigned concentrations of 100 U/mL and 460 accounting for the serum dilution factor. The reference standard was composed of a pool of five 461 convalescent serum samples obtained >14 days after COVID-19 PCR diagnosis and was diluted 462 sequentially in antibody-depleted human serum. Three dilutions were used to increase the 463 likelihood that at least one result for any sample would fall within the useable range of the 464 standard curve. Assay results were reported in U/mL of IgG. The final assay results were 465 expressed as the geometric mean concentration of all sample dilutions that produced a valid 466 assay result within the assay range.

467 SARS-CoV-2 neutralisation assay.

468 The neutralisation assay used a previously described strain of SARS-CoV-2 (USA WA1/2020) 469 that had been rescued by reverse genetics and engineered by the insertion of an mNeonGreen (mNG) gene into open reading frame 7 of the viral genome³⁸. This reporter virus generates 470 471 similar plaque morphologies and indistinguishable growth curves from wild-type virus. Viral master stocks (2 x 10⁷ PFU/mL) were grown in Vero E6 cells as previously described³⁸. With 472 473 patient convalescent sera, the fluorescent neutralisation assay produced comparable results to the conventional plaque reduction neutralisation assay³⁹. Serial dilutions of heat-inactivated 474

sera were incubated with the reporter virus (2 x 10^4 PFU per well to yield a 10-30% infection 475 476 rate of the Vero CCL81 monolayer) for 1 hour at 37 °C before inoculating Vero CCL81 cell 477 monolayers (targeted to have 8,000 to 15,000 cells in a central field of each well at the time of 478 seeding, 24 hours before infection) in 96-well plates to allow accurate quantification of infected 479 cells. Total cell counts per well were enumerated by nuclear stain (Hoechst 33342) and 480 fluorescent virally infected foci were detected 16-24 hours after inoculation with a Cytation 7 481 Cell Imaging Multi-Mode Reader (BioTek) with Gen5 Image Prime version 3.09. Titers were 482 calculated in GraphPad Prism version 8.4.2 by generating a 4-parameter (4PL) logistical fit of 483 the percent neutralisation at each serial serum dilution. The 50% neutralisation titre (VNT₅₀) 484 was reported as the interpolated reciprocal of the dilution yielding a 50% reduction in 485 fluorescent viral foci.

486 VSV-SARS-CoV-2 S variant pseudovirus neutralisation assay.

487 Vesicular stomatitis virus (VSV)-SARS-CoV-2-S pseudoparticle generation and neutralisation assays were performed as previously described²⁴. Briefly, human codon optimized SARS-CoV-488 489 2 S (GenBank: MN908947.3) was synthesised (Genscript) and cloned into an expression 490 plasmid. SARS-CoV-2 complete genome sequences were downloaded from GISAID 491 nucleotide database (https://www.gisaid.org). Sequences were curated, and genetic diversity of 492 the S-encoding gene was assessed across high quality genome sequences using custom 493 pipelines. Amino acid substitutions were cloned into the S expression plasmid using site-494 directed mutagenesis. HEK293T cells (ATCC CRL-3216) were seeded (culture medium: 495 DMEM high glucose [Life Technologies] supplemented with 10% heat-inactivated FBS (Life 496 Technologies) and penicillin/streptomycin/L-glutamine [Life Technologies]) and transfected 497 the following day with S expression plasmid using Lipofectamine LTX (Life Technologies) 498 following the manufacturer's protocol. At 24 hours post-transfection at 37 °C, cells were

499	infected with the VSV Δ G:mNeon/VSV-G diluted in Opti-MEM (Life Technologies) at a
500	multiplicity of infection of 1. Cells were incubated 1 hour at 37 °C, washed to remove residual
501	input virus and overlaid with infection medium (DMEM high glucose supplemented with 0.7%
502	Low IgG bovine serum albumin [BSA, Sigma], sodium pyruvate [Life Technologies] and 0.5%
503	Gentamicin [Life Technologies]). After 24 hours at 37 °C, the medium containing VSV-SARS-
504	CoV-2-S pseudoparticles was collected, centrifuged at 3000 x g for 5 minutes to clarify and
505	stored at -80 °C until further use.
506	For pseudovirus neutralisation assays, Vero cells (ATCC CCL-81) were seeded in 96-well
507	plates in culture medium and allowed to reach approximately 85% confluence before use in the
508	assay (24 hours later). Sera were serially diluted 1:2 in infection medium starting with a 1:300
509	dilution. VSV-SARS-CoV-2-S pseudoparticles were diluted 1:1 in infection medium for a
510	fluorescent focus unit (ffu) count in the assay of ~1000. Serum dilutions were mixed 1:1 with
511	pseudoparticles for 30 minutes at room temperature prior to addition to Vero cells and
512	incubation at 37 °C for 24 hours. Supernatants were removed and replaced with PBS (Gibco),
513	and fluorescent foci were quantified using the SpectraMax i3 plate reader with MiniMax
514	imaging cytometer (Molecular Devices). Neutralisation titers were calculated in GraphPad
515	Prism version 8.4.2 by generating a 4-parameter logistical (4PL) fit of the percent neutralisation
516	at each serial serum dilution. The 50% pseudovirus neutralisation titre (pVNT50) was reported
517	as the interpolated reciprocal of the dilution yielding a 50% reduction in fluorescent viral foci.
518	IFNγ ELISpot.
519	IFNγ ELISpot analysis was performed ex vivo (without further in vitro culturing for expansion)

519 IFNγ ELISpot analysis was performed ex vivo (without further in vitro culturing for expansion)
520 using PBMCs depleted of CD4⁺ and enriched for CD8⁺ T cells (CD8⁺ effectors) or depleted of

CD8⁺ and enriched for CD4⁺ T cells (CD4⁺ effectors). Tests were performed in duplicate and 521 522 with a positive control (anti-CD3 monoclonal antibody CD3-2 [1:1,000; Mabtech]). Multiscreen filter plates (Merck Millipore) pre-coated with IFNy-specific antibodies 523 524 (ELISpotPro kit, Mabtech) were washed with PBS and blocked with X-VIVO 15 medium (Lonza) containing 2% human serum albumin (CSL-Behring) for 1-5 hours. Per well, 3.3 x 10⁵ 525 526 effector cells were stimulated for 16-20 hours with three overlapping peptide pools representing 527 different portions of the wild-type sequence of SARS-CoV-2 S (N-terminal pools S pool 1 [aa 528 1-643] and RBD [aa1-16 fused to aa 327-528], and the C-terminal S pool 2 [aa 633-1273]). 529 Bound IFNy was visualised using a secondary antibody directly conjugated with alkaline 530 phosphatase followed by incubation with 5-bromo-4-chloro-3'-indolyl phosphate (BCIP)/ nitro 531 blue tetrazolium (NBT) substrate (ELISpotPro kit, Mabtech). Plates were scanned using an AID 532 Classic Robot ELISPOT Reader and analysed by AID ELISPOT 7.0 software (AID Autoimmun 533 Diagnostika). Spot counts were displayed as mean values of each duplicate. T cell responses 534 stimulated by peptides were compared to effectors incubated with medium only as a negative 535 control using an in-house ELISpot data analysis tool (EDA), based on two statistical tests 536 (distribution-free resampling) according to Moodie et al.^{40,41}, to provide sensitivity while maintaining control over false positives. 537

538 To account for varying sample quality reflected in the number of spots in response to anti-CD3 539 antibody stimulation, a normalisation method was applied, enabling direct comparison of spot 540 counts and strength of response between individuals. This dependency was modelled in a log-541 linear fashion with a Bayesian model including a noise component (unpublished). For a robust 542 normalisation, each normalisation was sampled 10,000 times from the model and the median taken as normalised spot count value. Likelihood of the model: $\log \lambda_E = \alpha \log \lambda_P + \log \beta_i + \beta_i$ 543 $\sigma \varepsilon$, where λ_E is the normalized spot count of the sample; α is a stable factor (normally 544 distributed) common among all positive controls λ_P ; β_j is a sample *j* specific component 545

546 (normally distributed); and $\sigma \varepsilon$ is the noise component, of which σ is Cauchy distributed, and ε 547 is Student's-t distributed. β_i ensures that each sample is treated as a different batch.

548 Flow cytometry.

549 Cytokine-producing T cells were identified by intracellular cytokine staining. PBMCs thawed 550 and rested for 4 hours in OpTmizer medium supplemented with 2 µg/mL DNase I (Roche), 551 were restimulated with different portions of the wild-type sequence of SARS-CoV-2 S in 552 peptide pools described in the ELISpot section (2 µg/mL/peptide; JPT Peptide Technologies) 553 in the presence of GolgiPlug (BD) for 18 hours at 37 °C. Controls were treated with DMSO-554 containing medium. Cells were stained for viability and surface markers (CD3 BV421, 1:250; 555 CD4 BV480, 1:50; CD8 BB515, 1:100; all BD Biosciences) in flow buffer (DPBS [Gibco] 556 supplemented with 2% FBS [Biochrom], 2 mM ethylenediaminetetraacetic acid [EDTA; 557 Sigma-Aldrich]) for 20 minutes at 4 °C. Afterwards, samples were fixed and permeabilised 558 using the Cytofix/Cytoperm kit according to manufacturer's instructions (BD Biosciences). 559 Intracellular staining (CD3 BV421, 1:250; CD4 BV480, 1:50; CD8 BB515, 1:100; IFNy PE-560 Cy7, 1:50 [for HCS]; IFNy BB700, 1:250 [for participants]; IL-2 PE, 1:10; IL-4 APC, 1:500; 561 all BD Biosciences) was performed in Perm/Wash buffer for 30 minutes at 4 °C. Samples were 562 acquired on a fluorescence-activated cell sorter (FACS) VERSE instrument (BD Biosciences) 563 and analysed with FlowJo software version 10.6.2 (FlowJo LLC, BD Biosciences). S- and 564 RBD-specific cytokine production was corrected for background by subtraction of values 565 obtained with dimethyl sulfoxide (DMSO)-containing medium. Negative values were set to 566 zero. Cytokine production in Figure 4b was calculated by summing up the fractions of all CD4⁺ 567 T cells positive for either IFNy, IL-2 or IL-4, setting this sum to 100% and calculating the 568 fraction of each specific cytokine-producing subset thereof. Pseudocolor plot axes are in log10 569 scale.

570 Peptide/MHC multimer staining.

571 In order to select MHC-class I epitopes for multimer analysis, a mass spectrometry-based binding and presentation predictor^{42,43} was applied to 8-12 amino acid long peptide sequences 572 573 from the Spike glycoprotein derived from the GenBank reference sequence for SARS-CoV-2 574 (accession: NC 045512.2, https://www.ncbi.nlm.nih.gov/nuccore/NC 045512) and paired 575 with 18 MHC-class-I alleles with >5% frequency in the European population. Top predicted 576 epitopes were identified by setting thresholds to the binding percent-rank ($\leq 1\%$) and 577 presentation scores ($\geq 10^{-2.2}$). Peptides were manufactured at >90% purity. pMHC complexes 578 were refolded with the easYmer technology (easYmer® kit, ImmuneAware Aps), and complex 579 formation was validated in a bead-based flow cytometry assay according to the manufacturer's 580 instructions^{44,45}. Combinatorial labeling was used for dissecting the antigen specificity of T 581 cells utilizing two-color combinations of five different fluorescent labels to enable detection of up to ten different T cell populations per sample⁴⁶. For tetramerisation, streptavidin (SA)-582 fluorochrome conjugates were added: SA BV421, SA BV711, SA PE, SA PE-Cy7, SA APC 583 584 (all BD Biosciences). For three BNT162b2 vaccinated participants, individualized pMHC 585 multimer staining cocktails contained up to ten pMHC complexes, with each pMHC complex encoded by a unique two-color combination. PBMCs $(2x10^6)$ were stained ex vivo for 20 586 587 minutes at room temperature with each pMHC multimer cocktail at a final concentration of 588 4 nM in Brilliant Staining Buffer Plus (BSB Plus [BD Horizon[™]]). Surface and viability 589 staining was carried out in flow buffer (DPBS [Gibco] with 2% FBS [Biochrom], 2 mM EDTA [Sigma-Aldrich]) supplemented with BSB Plus for 30 minutes at 4 °C (CD3 BUV395, 1:50; 590 591 CD45RA BUV563, 1:200; CD27 BUV737, 1:200; CD8 BV480, 1:200; CD279 BV650, 1:20; 592 CD197 BV786, 1:15; CD4 BB515, 1:50; CD28 BB700, 1:100; CD38 PE-CF594, 1:600; HLA-593 DR APC-R700, 1:150; all BD Biosciences; DUMP channel: CD14 APC-eFluor780, 1:100; CD16 APC-eFluor780, 1:100; CD19 APC-eFluor780, 1:100; fixable viability dye eFluor780, 594

595 1:1,667; all ThermoFisher Scientific). Cells were fixed for 15 minutes at 4 °C in 1x Stabilization

596 Fixative (BD), acquired on a FACSymphony[™] A3 flow cytometer (BD Biosciences) and 597 analysed with FlowJo software version 10.6.2 (FlowJo LLC, BD Biosciences). CD8⁺ T cell 598 reactivities were considered positive, when a clustered population was observed that was 599 labelled with only two pMHC multimer colors.

600 Statistical analysis.

601 The sample size for the reported part of the study was not based on statistical hypothesis testing.

602 All participants with data available were included in the safety and immunogenicity analyses.

603 The statistical method of aggregation used for the analysis of antibody concentrations and titers

604 is the geometric mean and the corresponding 95% CI. Employing the geometric mean accounts

605 for non-normal distribution of antibody concentrations and titers spanning several orders of

606 magnitude. Spearman correlation was used to evaluate the monotonic relationship between non-

607 normally distributed data sets.

All statistical analyses were performed using GraphPad Prism software version 8.4.2.

609 Data availability.

610 The data that support the findings of this study are available from the corresponding author 611 upon reasonable request. Upon completion of this clinical trial, summary-level results will be

612 made public and shared in line with data sharing guidelines.

613 **References**

- 614 1. Walsh, E. E. *et al.* Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine
- 615 Candidates. N. Engl. J. Med. NEJMoa2027906 (2020). doi:10.1056/NEJMoa2027906
- 616 2. Pardi, N. et al. Nucleoside-modified mRNA vaccines induce potent T follicular helper
- and germinal center B cell responses. J. Exp. Med. 215, 1571–1588 (2018).
- 618 3. Rauch, S., Jasny, E., Schmidt, K. E. & Petsch, B. New Vaccine Technologies to Combat
 619 Outbreak Situations. *Front. Immunol.* 9, (2018).
- 4. Pardi, N. *et al.* Expression kinetics of nucleoside-modified mRNA delivered in lipid
 nanoparticles to mice by various routes. *J. Control. Release* 217, 345–351 (2015).
- 5. Sahin, U., Kariko, K. & Tureci, O. mRNA-based therapeutics developing a new class
 of drugs. *Nat. Rev. Drug Discov.* 13, 759–780 (2014).
- 6. Pardi, N. *et al.* Nucleoside-modified mRNA immunization elicits influenza virus
 hemagglutinin stalk-specific antibodies. *Nat. Commun.* 9, 3361 (2018).
- 626 7. Pardi, N. *et al.* Zika virus protection by a single low-dose nucleoside-modified mRNA
 627 vaccination. *Nature* 543, 248–251 (2017).
- 8. Pardi, N. *et al.* Characterization of HIV-1 nucleoside-modified mRNA vaccines in
 rabbits and rhesus macaques. *Mol. Ther. Nucleic Acids* 15, 36–47 (2019).
- 630 9. Mulligan, M. J. *et al.* Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults.
 631 *Nature* (2020). doi:10.1038/s41586-020-2639-4
- 632 10. Sahin, U. *et al.* COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T-cell
 633 responses. *Nature* (2020). doi:10.1038/s41586-020-2814-7
- 634 11. Holtkamp, S. *et al.* Modification of antigen-encoding RNA increases stability,
 635 translational efficacy, and T-cell stimulatory capacity of dendritic cells. *Blood* 108,

- 636 4009–4017 (2006).
- 637 12. Orlandini von Niessen, A. G. et al. Improving mRNA-Based Therapeutic Gene Delivery
- 638 by Expression-Augmenting 3' UTRs Identified by Cellular Library Screening. *Mol. Ther.*
- **6**39 **27**, 824–836 (2019).
- Karikó, K. *et al.* Incorporation of pseudouridine into mRNA yields superior
 nonimmunogenic vector with increased translational capacity and biological stability. *Mol. Ther.* 16, 1833–40 (2008).
- 643 14. Wrapp, D. *et al.* Cryo-EM structure of the 2019-nCoV spike in the prefusion
 644 conformation. *Science* 367, 1260–1263 (2020).
- 645 15. BNT162b vaccines are immunogenic and protect non-human primates against SARS646 CoV-2. *Nature* in revisio, (2020).
- 647 16. Sahin, U. *et al.* An RNA vaccine drives immunity in checkpoint-inhibitor-treated
 648 melanoma. *Nature* 585, 107–112 (2020).
- Kamphuis, E., Junt, T., Waibler, Z., Forster, R. & Kalinke, U. Type I interferons directly
 regulate lymphocyte recirculation and cause transient blood lymphopenia. *Blood* 108,
 3253–61 (2006).
- Tsai, M. Y. *et al.* Effect of influenza vaccine on markers of inflammation and lipid
 profile. *J. Lab. Clin. Med.* 145, 323–7 (2005).
- Taylor, D. N. *et al.* Development of VAX128, a recombinant hemagglutinin (HA)
 influenza-flagellin fusion vaccine with improved safety and immune response. *Vaccine* **30**, 5761–9 (2012).
- Doener, F. *et al.* RNA-based adjuvant CV8102 enhances the immunogenicity of a
 licensed rabies vaccine in a first-in-human trial. *Vaccine* 37, 1819–1826 (2019).


- Destexhe, E. *et al.* Evaluation of C-reactive protein as an inflammatory biomarker in
 rabbits for vaccine nonclinical safety studies. *J. Pharmacol. Toxicol. Methods* 68, 367–
 73 (2013).
- 662 22. Kaech, S. M., Wherry, E. J. & Ahmed, R. Effector and memory T-cell differentiation:
- 663 implications for vaccine development. *Nat. Rev. Immunol.* **2**, 251–62 (2002).
- 664 23. Pérez-Mazliah, D., Ndungu, F. M., Aye, R. & Langhorne, J. B-cell memory in malaria:
 665 Myths and realities. *Immunol. Rev.* 293, 57–69 (2020).
- 666 24. Baum, A. *et al.* Antibody cocktail to SARS-CoV-2 spike protein prevents rapid 667 mutational escape seen with individual antibodies. *Science* **369**, 1014–1018 (2020).
- 25. Zhang, L. *et al.* The D614G mutation in the SARS-CoV-2 spike protein reduces S1
 shedding and increases infectivity. *bioRxiv Prepr. Serv. Biol.* (2020). doi:bioRxiv:
 10.1101/2020.06.12.148726
- 671 26. Sette, A. *et al.* Selective CD4+ T cell help for antibody responses to a large viral
 672 pathogen: deterministic linkage of specificities. *Immunity* 28, 847–58 (2008).
- Cameron, M. J., Bermejo-Martin, J. F., Danesh, A., Muller, M. P. & Kelvin, D. J. Human
 immunopathogenesis of severe acute respiratory syndrome (SARS). *Virus Res.* 133, 13–
 9 (2008).
- Tang, F. *et al.* Lack of peripheral memory B cell responses in recovered patients with
 severe acute respiratory syndrome: a six-year follow-up study. *J. Immunol.* 186, 7264–8
 (2011).
- Channappanavar, R., Fett, C., Zhao, J., Meyerholz, D. K. & Perlman, S. Virus-specific
 memory CD8 T cells provide substantial protection from lethal severe acute respiratory
 syndrome coronavirus infection. *J. Virol.* 88, 11034–44 (2014).
- 682 30. Ni, L. et al. Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in

- 683 COVID-19 Convalescent Individuals. *Immunity* **52**, 971-977.e3 (2020).
- 684 31. Grifoni, A. et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans
- 685 with COVID-19 Disease and Unexposed Individuals. *Cell* **181**, 1489-1501.e15 (2020).
- 686 32. Giménez, E. *et al.* SARS-CoV-2-reactive interferon-γ-producing CD8+ T cells in
 687 patients hospitalized with coronavirus disease 2019. *J. Med. Virol.* (2020).
 688 doi:10.1002/jmv.26213
- Braun, J. *et al.* Presence of SARS-CoV-2 reactive T cells in COVID-19 patients and
 healthy donors. *medRxiv* (2020). doi:10.1101/2020.04.17.20061440
- 691 34. Liu, W. J. *et al.* T-cell immunity of SARS-CoV: Implications for vaccine development
 692 against MERS-CoV. *Antiviral Res.* 137, 82–92 (2017).
- 5. Lu, R. *et al.* Genomic characterisation and epidemiology of 2019 novel coronavirus:
 implications for virus origins and receptor binding. *Lancet (London, England)* 395, 565–
 574 (2020).
- 696 36. Shomuradova, A. S. *et al.* SARS-CoV-2 epitopes are recognized by a public and diverse
 697 repertoire of human T cell receptors. *Immunity* (2020).
 698 doi:10.1016/j.immuni.2020.11.004
- 699 37. Peng, Y. *et al.* Broad and strong memory CD4+ and CD8+ T cells induced by SARS700 CoV-2 in UK convalescent individuals following COVID-19. *Nat. Immunol.* 21, 1336–
 701 1345 (2020).
- 38. Xie, X. *et al.* An Infectious cDNA Clone of SARS-CoV-2. *Cell Host Microbe* 27, 841848.e3 (2020).
- 39. Muruato, A. E. *et al.* A high-throughput neutralizing antibody assay for COVID-19
 diagnosis and vaccine evaluation. *bioRxiv Prepr. Serv. Biol.* Accepted at Nat Comun.
- 706 (2020). doi:bioRxiv: 10.1101/2020.05.21.109546

707	40.	Moodie, Z., Huang, Y., Gu, L., Hural, J. & Self, S. G. Statistical positivity criteria for
708		the analysis of ELISpot assay data in HIV-1 vaccine trials. J. Immunol. Methods 315,
709		121–32 (2006).

- 41. Moodie, Z. *et al.* Response definition criteria for ELISPOT assays revisited. *Cancer Immunol. Immunother.* 59, 1489–501 (2010).
- Abelin, J. G. *et al.* Mass Spectrometry Profiling of HLA-Associated Peptidomes in
 Mono-allelic Cells Enables More Accurate Epitope Prediction. *Immunity* 46, 315–326
 (2017).
- Poran, A. *et al.* Sequence-based prediction of SARS-CoV-2 vaccine targets using a mass
 spectrometry-based bioinformatics predictor identifies immunogenic T cell epitopes. *Genome Med.* 12, 70 (2020).
- 44. Svitek, N. *et al.* Use of 'one-pot, mix-and-read' peptide-MHC class I tetramers and
 predictive algorithms to improve detection of cytotoxic T lymphocyte responses in cattle. *Vet. Res.* 45, 50 (2014).
- 45. Leisner, C. *et al.* One-pot, mix-and-read peptide-MHC tetramers. *PLoS One* 3, e1678
 (2008).
- 46. Hadrup, S. R. *et al.* Parallel detection of antigen-specific T-cell responses by
 multidimensional encoding of MHC multimers. *Nat. Methods* 6, 520–6 (2009).
- 725 47. U.S. Department of Health and Human Services, Administration, F. and D. & Research, 726 C. for B. E. and. Toxicity grading scale for healthy adult and adolescent volunteers 727 enrolled preventive vaccine clinical trials. (2007). Available in at: 728 https://www.fda.gov/regulatory-information/search-fda-guidance-documents/toxicitygrading-scale-healthy-adult-and-adolescent-volunteers-enrolled-preventive-vaccine-729 730 clinical.

Figures 731




732

Figure 1 | BNT162b2-induced IgG concentrations and virus neutralisation titers. 733

734 Vaccination schedule and serum sampling are described in Extended Data Fig. 1. Participants 735 were immunised with BNT162b2 on days 1 and 22 (*n*=12 per dose cohort; from day 22 onwards 736 n=11 for the 1 µg and 10 µg dose cohorts). Arrowheads indicate days of vaccination. Pre-dose 737 responses across all dose levels were combined. COVID-19 human convalescent samples 738 (HCS, *n*=38) were obtained at least 14 days after PCR-confirmed diagnosis and at a time when 739 the donors were no longer symptomatic. Each serum was tested in duplicate and geometric 740 mean concentrations (GMCs) (a) and titers (GMTs) (b, e) were plotted. For values below the 741 lower limit of quantification (LLOQ; 1.27 [a], 20 [b], 300 [c]), LLOQ/2 values were plotted. 742 Group GMCs or GMTs (values above bars) with 95% confidence interval. a, Recombinant S1-743 binding IgG GMC. b, SARS-CoV-2 50% neutralisation titers (VNT₅₀) in immunised 744 participants and HCS. c, Nonparametric Spearman correlation of recombinant S1-binding IgG 745 GMCs (as in [a]) with VNT₅₀ from day 29 sera (as in [b]) with data points for participants with 746 GMCs and GMTs below the LLOQ (open circles) excluded. d, Pseudovirus 50% neutralisation

- titers (pVNT₅₀) across a pseudovirus panel displaying 19 SARS-CoV-2 S variants including 18
- 748 RBD mutants and the dominant S variant D614G (dose levels 10, 30 and 50 µg, n=1-2
- representative sera each; day 29).






751 Figure 2 | Incidence and magnitude of BNT162b2-induced T cell responses.

752 PBMCs obtained on day 1 (pre-prime) and day 29 (7 days post-boost) (dose cohorts 1, 10 and 753 20 µg, n=9 each; 30 µg, n=10) were enriched for CD4⁺ or CD8⁺ T cell effectors and separately 754 stimulated over night with three overlapping peptide pools representing different portions of 755 the wild-type sequence of SARS-CoV-2 S (N-terminal pools S pool 1 and RBD, and the C-756 terminal S pool 2), for assessment in direct ex vivo IFNy ELISpot. Common pathogen T cell 757 epitope pools CEF (immune dominant HLA class I epitopes of CMV, EBV, influenza virus) 758 and CEFT (immune dominant HLA class II epitopes CMV, EBV, influenza virus, tetanus 759 toxoid) were used as controls. Cell culture medium served as negative control. Each dot 760 represents the normalised mean spot count from duplicate wells for one study participant, after subtraction of the medium-only control (a, c). a, Antigen-specific $CD4^+$ and $CD8^+$ T cell 761 762 responses for each dose cohort. The number of participants with a detectable T cell response on 763 day 29 over the total number of tested participants per dose cohort is provided. Spot count data 764 from two participants from the 20 µg dose cohort could not be normalised and are not plotted. 765 **b**, Example of CD4⁺ and CD8⁺ ELISpot for a 30 µg dose cohort participant. **c**, S-specific T cell

- 766 responses in all participants who recognised either S peptide pool and their baseline CEFT- and
- CEF-specific T cell responses. Horizontal bars indicate median values. 767




768

769 Figure 3 | Cytokine polarisation of BNT162b2-induced T cells.

770 PBMCs obtained on day 1 (pre-prime) and day 29 (7 days post-boost) (dose cohorts 1 μ g, n=8; 10 and 30 μ g, *n*=10 each; 20 μ g, *n*=9) and COVID-19 recovered donors (HCS, *n*=18; c, d) were 771 772 stimulated over night with three overlapping peptide pools representing different portions of 773 the wild-type sequence of SARS-CoV-2 S (N-terminal pools S pool 1 [aa 1-643] and RBD [aa1-16 fused to aa 327-528 of S], and the C-terminal S pool 2 [aa 633-1273]), and analysed by flow 774 775 cytometry (for gating strategy see Supplementary Fig. 1). a, Example of pseudocolor flow 776 cytometry plots of cytokine-producing CD4⁺ and CD8⁺ T cells from a 30 µg dose cohort 777 participant in response to S pool 1. **b**, S-specific CD4⁺ T cells producing the indicated cytokine 778 as a fraction of total cytokine-producing S-specific CD4⁺ T cells in response to S pool 1 and S

- pool 2. CD4 non-responders (<0.03% total cytokine producing T cells: 1 μ g, *n*=2 [S pool 1]
- and n=1 [S pool 2]; 10 µg, n=1) were excluded. Arithmetic mean with 95% confidence interval.
- 781 c, S-specific CD4⁺ (S pool 1, S pool 2 and RBD) and d, CD8⁺ T cells (S pool 1, S pool 2 and
- RBD) producing the indicated cytokine as a fraction of total circulating T cells of the same
- subset. Values above data points indicate mean fractions per dose cohort. Participant PBMCs
- 784 were tested as single instance (**b-d**).






786 Figure 4 | Characterization of BNT162b2-induced T cells on the single epitope level.

787 PBMCs obtained on day 1 (pre-prime) and day 29 (7 days post-boost) of three vaccinated 788 participants (dose cohorts 10 μ g, n=1; 30 μ g, n=2) were stained with individual pMHC class I 789 multimer cocktails and analysed for T cell epitope specificity (a) and phenotype (b; example from participant 3; YLQPRTFLL) by flow cytometry (for gating strategy see Supplementary 790 791 Fig. 2). Peptide sequences above dot plots indicate pMHC class I multimer epitope specificity, 792 numbers above dot plots indicate the amino acids corresponding to the epitope within S. c, 793 Localization of identified MHC class I-restricted epitopes within S.


Extended Data Figures and Tables 794



795

796 Extended Data Figure 1 | Schedule of vaccination and assessment.

- 797 Study participants received a priming immunisation with BNT162b2 on day 1, and a booster
- 798 immunisation on day 22±2. Serum was obtained on days 1 (pre-prime), 8±1 (post-prime), 22±2
- 799 (pre-boost), 29±3, 43±4, 50±4 and 85±7 (post-boost). PBMCs were obtained on days 1 (pre-
- 800 prime) and 29±3 (post-boost).




801

802 Extended Data Figure 2 | Solicited adverse events.

803 Number of participants with local (a) or systemic solicited adverse events (AE) (b). Participants 804 were immunised with BNT162b2 on days 1 and 22 (prime: *n*=12 per dose cohort; boost: 1, 805 10 µg, n=11); discontinuation of participants due to non-vaccine related reasons). Grey shading 806 indicates number of participants at each time point. As per protocol, AEs were recorded up to 807 7 days after each immunisation (days 1-7 and 22-28) to determine reactogenicity; for some


- 808 participants, 1-3 additional days of follow-up were available. Grading of adverse events was
- 809 performed according to US Food and Drug Administration (FDA) recommendations⁴⁷.



810

811 Extended Data Figure 3 | Pharmacodynamic markers.


Participants were immunised with BNT162b2 on days 1 and 22 (n=12 per dose cohort). One participant in the 1 µg dose cohort (outlier on day 8 in [a] and highest data set in [b]) presented with a non-treatment related gastroenteritis on days 6 to 8. **a**, Kinetics of C-reactive protein (CRP) level. **b**, Kinetics of lymphocyte counts. **c**, Kinetics of neutrophil counts. Dotted lines indicate upper and lower limit of reference range. For values below the lower limit of quantification (LLOQ) = 0.3, LLOQ/2 values were plotted (**a**).




818

819 Extended Data Figure 4 | BNT162b2-induced RBD-specific IgG concentrations.

820 Recombinant RBD-binding IgG geometric mean concentration in participants immunised with 821 BNT162b2 on days 1 and 22 (n=12 per dose cohort; from day 22 onwards n=11 for the 1 µg 822 and 10 µg dose cohorts). Vaccination schedule and serum sampling are described in Extended 823 Data Fig. 1. Arrowheads indicate days of vaccination. Pre-dose responses across all dose levels 824 were combined. COVID-19 convalescent samples (HCS, n=38) were obtained at least 14 days 825 after PCR-confirmed diagnosis and at a time when the donors were no longer symptomatic. 826 Each serum was tested in duplicate and geometric mean concentrations plotted. For values 827 below LLOQ = 1.15, LLOQ/2 values were plotted. Group geometric mean concentrations 828 (values above bars) with 95% confidence interval.






829

831 CD4⁺ or CD8⁺ T cell effector-enriched fractions of immunised participants derived from 832 PBMCs obtained on day 1 (pre-prime) and day 29 (7 days post-boost) (1, 10 and 20 µg dose 833 cohorts, n=9 each; 30 µg dose cohort, n=10) were stimulated overnight with two overlapping 834 peptide pools covering the wild-type SARS-CoV-2 S (S pool 1 and S pool 2) for assessment in 835 direct ex vivo IFNy ELISpot (a-c). Each dot represents the normalised mean spot count from 836 duplicate wells for one study participant, after subtraction of the medium-only control. T cell 837 responses against S pool 1 and S pool 2 per participant were combined. Spot count data from 838 two participants from the 20 µg dose cohort could not be normalised and are not plotted. 839 PBMCs from vaccinated participants on day 29 (7 days post-boost) (dose cohorts 1 μ g, n=7; 840 10 and 30 μ g, n=10; 20 μ g, n=9) were stimulated as described above and analysed by flow 841 cytometry (d, e). a, S-specific CD4⁺ and CD8⁺ T cell responses for each dose cohort. Number 842 of participants with detectable T cell response on day 29 over the total number of tested participants per dose cohort is provided. b, Mapping of vaccine-induced responses of 843

medRxiv preprint doi: https://doi.org/10.1101/2020.12.09.20245175; this version posted December 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

844 participants with evaluable baseline data (n=34 for CD4⁺ and n=37 for CD8⁺ T cell responses) 845 to different portions of S. De novo induced or amplified responses are classified as BNT162b2-846 induced response; no responses or pre-existing responses that were not amplified by the 847 vaccinations are classified as no vaccine response (none). c, Response strength to S pool 1 in 848 individuals with or without a pre-existing response to S pool 2. Data from the 1 µg dose cohort 849 are excluded, as no baseline response to S pool 2 was present in this dose cohort. Horizontal 850 bars represent median of each group. d, Examples of pseudocolor flow cytometry plots of 851 cytokine-producing CD4⁺ and CD8⁺ T cells from a participant prime/boost vaccinated with 852 30 µg BNT162b2. e, Frequency of vaccine-induced, S-specific IFN γ^+ CD4⁺ T cells vs. IL4⁺ 853 CD4⁺ T cells. ICS stimulation was performed using a peptide mixture of S pool 1 and S pool 2. Each data point represents one study participant (1 µg dose cohort, n=8; 20 µg dose cohort, 854 855 n=8; 10 and 30 µg, n=10 each). One participant from the 20 µg dose cohort with a strong pre-856 existing $CD4^+$ T cell response to S pool 2 was excluded. **f**, Antigen-specific $CD8^+$ T cell 857 frequencies determined by pMHC class I multimer staining (% multimer⁺ of CD8⁺), ICS and 858 ELISpot (% IFN γ^+ of CD8⁺) for the three participants analysed in Figure 4. Signals for S pool 859 1 and S pool 2 were merged.



860

Extended Data Figure 6 | Correlation of antibody and T cell responses. 861

862 Data are plotted for all prime/boost vaccinated participants (dose cohorts 1, 10, 20 and 30 µg) 863 from day 29, with data points for participants with no detectable T cell response (open circles; 864 **b**, **c**) excluded from correlation analysis. S1-specific IgG responses as in Fig. 1a, S-specific T 865 cell responses as in Extended Data Fig. 5a (n=37). Nonparametric Spearman correlation. **a**, Correlation of S1-specific IgG responses with S-specific CD4⁺ T cell responses. **b**, Correlation 866 867 of S-specific CD4⁺ with CD8⁺ T cell responses. c, Correlation of S1-specific IgG responses 868 with S-specific $CD8^+$ T cell responses.

Extended Data Table 1 | Demographic characteristics. 869

Cohort		1 μg 10 μg (N=12) (N=12) n (%) n (%)		20 μg (N=12) n (%)	30 µg (N=12) n (%)	Total (N=48) n (%)	
C	Male	7 (58.3)	4 (33.3)	2 (16.7)	8 (66.7)	21 (43.8)	
Sex	Female	5 (41.7)	8 (66.7)	10 (83.3)	4 (33.3)	27 (56.2)	
	Caucasian	12 (100)	12 (100)	12 (100)	12 (100)	48 (100)	
Race	African American	0	0	0	0	0	
	Asian	0	0	0	0	0	
Age at vaccination (years)	Mean (SD)	36.1 (10.09)	34.8 (10.41)	42.3 (9.86)	46.7 (6.41)	39.9 (10.26)	
	Median	37.0	35.5	41.5	47.0	41.0	
	Min, Max	21, 53	19, 51	29, 55	35, 55	19, 55	

⁸⁷⁰

N, number of participants in the specified group. This value is the denominator for the 871

872 percentage calculations. n, number of participants with the specified characteristics.

873	Extended Data Table 2	Participant disposition and analysis sets.
015	Entended Data Table	i ui tielpunt disposition und undigsis sets.

	BNT162b2 vaccinated Safety analysis		/ analysis	Antibody analysis						T-cell analysis			
Cohort	Prime	Boost	Day 1+	Day 22±2+	Day 1	Day 8±1	Day 22±2	Day 29±3	Day 43±4	Day 50±4	Day 85±7	Day 1	Day 29±3
1 µg	12	11	12	11	12	12	12	11	10	10	0	9* (8)	9 (8)
10 µg	12	11	12	11	12	12	11	11	11	11	11	9** (10)	9 (10)
20 µg	12	12	12	12	12	12	12	12	12	12	10	9 (9)	9 (9)
30 µg	12	12	12	12	12	12	12	12	11	12	12	10 (10)	10 (10)

874

875 Twelve participants per dose cohort received the priming and the booster dose except for two 876 participants, who discontinued prior the booster dose due to a study drug-unrelated withdrawal 877 by the participant (1 µg dose) and an adverse event (10 µg; upper respiratory syndrome), 878 respectively. Safety analysis: Number of participants for whom 7 days of reactogenicity follow-879 up after both doses was evaluable at data cut-off. Antibody analysis: Numbers of participants 880 for whom virus neutralisation assays and S1- and RBD-binding IgG antibody assays were 881 performed. T cell analysis: Numbers of participants for whom PBMCs were available at data 882 cut-off and IFNy ELISpot and flow cytometry (in parentheses). N/A, not applicable. *8 and **7 883 for CD4⁺ T cell responses.

884 Extended Data Table 3a | Summary of solicited local reactions.

Time interval			10 µg (N=12)	20 µg (N=12)	30 µg (N=12)	Total (N=48)
	nn	12	12	12	12	48
Dose 1 up to day 7 after dose 1	Any local reaction, n (%)	6 (50)	12 (100)	12 (100)	10 (83)	40 (83)
	Any grade ≥3 local reaction, n (%)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Dose 2 up to day 7 after dose 2	nn	11	11	12	12	46
	Any local reaction, n (%)	4 (36)	10 (91)	10 (83)	11 (92)	35 (76)
	Any grade ≥3 local reaction, n (%)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	nn	12	12	12	12	48
Combined interval	Any local reaction, n (%)	7 (58)	12 (100)	12 (100)	11 (92)	42 (88)
	Any grade ≥3 local reaction, n (%)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

885

886 Extended Data Table 3b | Summary of solicited systemic reactions.

Time interval	1 µg (N=12)	10 µg (N=12)	20 µg (N=12)	30 µg (N=12)	Total (N=48)	
	nn	12	12	12	12	48
Dose 1 up to day 7 after dose 1	Any systemic reaction, n (%)		12 (100)	9 (75)	9 (75)	39 (81)
	Any grade ≥3 systemic reaction, n (%)	0 (0)	0 (0)	1 (8)	0 (0)	1 (2)
Dose 2 up to day 7 after dose 2	nn	11	11	12	12	46
	Any systemic reaction, n (%)	4 (36)	7 (64)	10 (83)	10 (83)	31 (67)
	Any grade ≥3 systemic reaction, n (%)	0 (0)	1 (9)	1 (8)	3 (25)	5 (12)
	nn	12	12	12	12	48
Combined interval	Any systemic reaction, n (%)	9 (75)	12 (100)	11 (92)	12 (100)	44 (92)
	Any grade ≥3 systemic reaction, n (%)	0 (0)	1 (8)	2 (17)	3 (25)	6 (13)

887

888 The combined interval is the union of the intervals 'Dose 1 up to day 7 after dose 1' and 'Dose 889 2 up to day 7 after dose 2'. N = number of participants in the analysis set; n = number of 890 participants with the respective local (a) or systemic (b) reactions; nn = number of participants 891 with any information on local (a) or systemic (b) reactions available.